Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APVO436 + venetoclax + azacitidine
- Development stage
- Unknown
- Lead developer
- Aptevo Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
APVO436 + venetoclax + azacitidine is an investigational **triplet drug regimen** for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), primarily in newly diagnosed, relapsed, or refractory patients. APVO436 is a humanized bispecific monoclonal antibody targeting CD123 on AML cells and CD3 on T cells, thereby redirecting T cell cytotoxicity against leukemic stem cells and blasts. Venetoclax is a small molecule inhibitor of B-cell lymphoma 2 (BCL-2), promoting apoptosis in malignant cells. Azacitidine is a pyrimidine nucleoside analog inhibiting DNA/RNA methyltransferases, resulting in cytotoxicity and epigenetic modulation. This combination is designed to target leukemic stem cells, induce apoptosis, and alter epigenetic regulation to overcome disease resistance, and has demonstrated encouraging remission and survival duration in treatment-naïve or refractory AML patients[1][3][5][7].
- Other names
- APVO436 + venetoclax + azacitidine
02
Targets
IL3RA (Interleukin 3 Receptor)BCL-2 (BCL-2 family)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on APVO436 + venetoclax + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APVO436 + venetoclax + azacitidine.